# Risk Assessment: ZTS (Zoetis Inc.)

## Fecha: 2026-02-12

## Risk Score: HIGH

**Rationale:** Multiple converging risks -- Librela safety crisis actively destroying a $568M franchise (-11% Q4, -32% US Q4), EU antitrust investigation with novel abuse-of-dominance theory, veterinary visit secular decline, and growth deceleration from 6% to 3-5% guidance. The combination of a product safety crisis (Librela) simultaneous with a cyclical headwind (vet visit decline) and regulatory overhang (EU antitrust) creates correlated downside that individually would be MEDIUM but together constitute HIGH.

---

## Matriz de Riesgos

| # | Categoria | Riesgo | Probabilidad | Impacto | Score | Mitigante |
|---|-----------|--------|-------------|---------|-------|-----------|
| 1 | Fundamental | Librela/Solensia safety crisis destroys OA pain franchise | Alta | Alto | CRITICAL | Pivoting to next-gen mAb; 21M+ doses globally with "rare" adverse rate |
| 2 | Fundamental | Veterinary visit secular decline (-2-4% YoY) | Alta | Medio | HIGH | International markets growing; diagnostics less visit-dependent |
| 3 | Regulatory | EU antitrust investigation (abuse of dominance) | Media | Alto | HIGH | Novel legal theory, unlikely to set broad precedent per experts |
| 4 | Competitive | Apoquel generic entry pre-2030 ($1.3B dermatology at risk) | Media | Alto | HIGH | Cytopoint biosimilars not until 2031-2034; rational competitor pricing in animal health |
| 5 | Fundamental | Growth deceleration from 6% to 3-5% (structural, not cyclical) | Alta | Medio | HIGH | International livestock strong (+12% organic); innovation pipeline |
| 6 | Financiero | Aggressive buyback-funded-by-debt strategy ($1.75B convertible at $148.20) | Media | Medio | MEDIUM | ND/EBITDA 1.3x manageable; interest coverage 14.9x; convert at $148.20 well above current price |
| 7 | ESG | Antibiotic resistance regulations tighten | Media | Medio | MEDIUM | Vaccine-heavy portfolio positions well; but livestock antibiotics still meaningful |
| 8 | Macro | Pet spending recession / consumer pullback | Alta | Bajo | LOW | Animal health is semi-defensive; historical resilience in recessions |
| 9 | Geopolitico | Tariff impact on international operations (~50% international) | Media | Bajo | LOW | Mostly local manufacturing; limited cross-border trade of finished products |
| 10 | Valoracion | Value trap / dead money if vet visits don't recover | Media | Medio | MEDIUM | At 21x P/E near 52wL, already de-rated significantly |
| 11 | Fundamental | GLP-1 drugs for pets emerge as new market | Baja | Medio | LOW | Early stage (cats only); Zoetis could develop own version; not competitive with dermatology |
| 12 | Competitivo | IDEXX dominates veterinary diagnostics; Zoetis distant #2 | Media | Bajo | LOW | Diagnostics is growth driver but not core profit engine; VetScan OptiCell AI launch |
| 13 | Financiero | Convertible bond dilution risk if stock recovers above $148.20 | Media | Bajo | LOW | Capped call transactions limit dilution; management chose structure deliberately |
| 14 | Legal | Securities class action / shareholder lawsuits re: Librela disclosure | Media | Bajo | LOW | Ambulance-chasing law firms; no SEC enforcement action; disclosure appears adequate |

### Scoring Reference:
- Alta x Alto = CRITICAL
- Alta x Medio OR Media x Alto = HIGH
- Media x Medio = MEDIUM
- Baja x cualquiera OR cualquiera x Bajo = LOW

---

## Top 3 Riesgos Criticos

### 1. Librela/Solensia Safety Crisis -- CRITICAL

- **Categoria:** Fundamental / Regulatory / Legal
- **Descripcion:** Zoetis' osteoarthritis pain monoclonal antibody franchise (Librela for dogs, Solensia for cats) has been hit by a safety crisis. The FDA issued a "Dear Veterinarian" letter about adverse events including neurologic signs (ataxia, seizures, paresis), urinary issues, and death. In February 2025, the FDA also found that Zoetis' YouTube marketing videos made "false or misleading claims" about Librela/Solensia safety. Thousands of adverse event reports have been filed. A dedicated consumer advocacy website (stopzoetis.org) has emerged.
- **Evidencia:**
  - OA pain franchise declined 3% operationally in FY2025 to $568M, with Q4 declining 11%
  - Librela US revenue declined 16% in FY2025, with Q4 US declining 32% ($36M quarterly revenue)
  - Librela globally declined 6% in FY2025
  - FDA "Dear Veterinarian" letter issued
  - FDA February 2025 warning about misleading YouTube marketing
  - Block & Leviton investigating for potential securities law violations
  - 3,800+ adverse event reports through end of 2023 alone (cumulative is higher)
- **Probabilidad:** Alta -- this is already happening, not a hypothetical risk. The franchise is in active decline.
- **Impacto si materializa plenamente:** $568M franchise could shrink by 30-50% over 2-3 years if vet confidence doesn't recover. This represents ~6% of total company revenue. Combined with legal liability, total impact could reach 10-15% hit to equity value. A worst-case scenario where the franchise approaches zero and legal settlements are material could mean a 20-25% downside from current levels.
- **Mitigante:** Zoetis states 21M+ doses globally with adverse event rate below "rare" (EMA definition: <10 per 10,000). International Librela was flat-to-up (+2% operationally). Company is pivoting to "multipronged strategy" for OA. However, vet confidence is the key variable and hard to rebuild.
- **Kill condition?:** YES -- If Librela receives FDA-mandated label change restricting use, or if the adverse event profile worsens with additional mortality data, or if US Librela revenue declines >50% YoY for 2 consecutive quarters. This would indicate permanent franchise impairment.

### 2. EU Antitrust Investigation (Abuse of Dominance -- Ranevetmab)

- **Categoria:** Regulatory / Legal
- **Descripcion:** The European Commission opened a formal antitrust investigation in March 2024 into whether Zoetis abused its dominant position in the market for biological treatments for chronic pain in dogs. The allegation is that Zoetis acquired Nexvet Biopharma in 2017 (which had ranevetmab, a competing mAb to Librela), developed both products in parallel for 2 years, then deliberately shelved ranevetmab to eliminate a competitor. Virbac, which had rights to ranevetmab, filed the initial complaint in November 2020. EC conducted dawn raids in October 2021.
- **Evidencia:**
  - EC formal investigation opened (first-ever abuse of dominance case for shelving a pipeline product)
  - Dawn raids conducted at Zoetis premises in Belgium (October 2021)
  - Virbac complaint filed November 2020
  - Novel legal theory: EC is testing whether acquiring and shelving a competitor product constitutes abuse
  - Case is still pending as of 2026
- **Probabilidad:** Media -- the legal theory is novel and untested. Experts say it's unlikely to succeed easily. However, the EC has invested significant resources (dawn raids, formal investigation) suggesting they believe they have a case.
- **Impacto si materializa:** A finding of abuse of dominance could result in a fine of up to 10% of global annual turnover (up to ~$950M). More importantly, it could force Zoetis to license ranevetmab to Virbac, creating a direct biological competitor to Librela in the EU. This would be doubly damaging given Librela's current US weakness -- if international markets also face competition, the OA franchise collapse accelerates. Total equity impact: 10-20% downside. Even without a full finding, the reputational damage in Europe and the precedent for future acquisitions would be meaningful.
- **Mitigante:** Novel legal theory makes conviction uncertain. Experts indicate it's "unlikely to deter innovation" broadly. Settlement is possible. Timeline is long (formal investigation since 2024, could take 2-4 more years).
- **Kill condition?:** YES -- If EC issues a Statement of Objections finding abuse of dominance AND orders ranevetmab licensing to Virbac. This would create a biological competitor in the EU market where Librela international has been more resilient.

### 3. Generic Entry for Apoquel / Dermatology Franchise Erosion

- **Categoria:** Competitive
- **Descripcion:** Zoetis' dermatology franchise (Apoquel + Cytopoint) represents ~$1.3B in revenue (~14% of total) with a dominant 95% market share. Apoquel (oclacitinib) is a small molecule JAK inhibitor that will face generic competition before 2030. Cytopoint (lokivetmab) is a biologic where biosimilars are not expected until 2031-2034. However, dermatology growth already decelerated to just 1% in Q4 2025, suggesting the franchise may be maturing even before generics arrive.
- **Evidencia:**
  - Apoquel generics expected before 2030; estimated peak generic share of 20% within 5 years of first entry
  - Dermatology franchise grew just 1% in Q4 2025 (near stagnation)
  - Cytopoint biosimilars estimated 2031-2034 (longer protection)
  - Animal health generics market is "rational" -- competitors don't typically price as aggressively as human pharma generics
  - However, Elanco and Boehringer Ingelheim are both investing in dermatology
- **Probabilidad:** Media -- generic entry before 2030 is near-certain for Apoquel. The question is how much market share they capture and at what price erosion.
- **Impacto si materializa:** Apoquel is roughly half the dermatology franchise (~$650M). A 20% generic share at 30% price discount would reduce Apoquel revenue by ~$200M, or ~2% of total revenue. However, if generic pricing is more aggressive (unlikely but possible in animal health) or share capture is higher, impact could reach 3-5% of total revenue. On a P/E basis, this could mean $5-10 downside per share.
- **Mitigante:** Animal health generics market is more rational than human pharma. Relationships between competitors are less adversarial. Zoetis has brand loyalty and vet relationships. Cytopoint (biologic) is protected until 2031-2034 and is harder to biosimilar. However, the 1% Q4 growth suggests maturation is already happening.
- **Kill condition?:** NO -- but should be monitored. Becomes a kill condition if generics launch AND Zoetis cannot offset with new products, AND dermatology revenue declines >10% YoY.

---

## Riesgos Adicionales (Detalle)

### 4. Veterinary Visit Secular Decline

- **Descripcion:** US veterinary clinic visits have been declining 2-4% YoY. The veterinary industry entered a recessionary phase in late 2024, with forecasts suggesting persistent negative growth through mid-2026. 64% of pet owners earning <$36K and 72% earning $36-60K say they cannot afford veterinary care costs. Piper Sandler downgraded ZTS to Neutral specifically citing vet visit decline.
- **Probabilidad:** Alta -- this is already happening.
- **Impacto:** Medio -- Zoetis' US companion animal business (roughly 45% of total) is directly impacted. However, international markets (+8% in Q4) and livestock are less affected.
- **Quantification:** A sustained 3% decline in US vet visits likely translates to 1-2% drag on total company revenue, or $100-200M.

### 5. Growth Deceleration (6% to 3-5%)

- **Descripcion:** 2026 guidance of 3-5% organic operational revenue growth represents a meaningful deceleration from the 6% achieved in FY2025 and from the company's historical ~7% organic growth rate. The combination of Librela decline, vet visit weakness, and dermatology maturation suggests this deceleration may not be entirely cyclical.
- **Probabilidad:** Alta -- this is management's own guidance.
- **Impacto:** Medio -- a permanent shift from 6-7% grower to 3-5% grower would warrant a lower multiple. At 21x current P/E, if the market reprices to 18-19x (slower growth), downside is 10-15%.

### 6. Aggressive Buyback-Funded-by-Debt Strategy

- **Descripcion:** Zoetis returned $3.2B in buybacks + $800M in dividends in 2025, funded partly by a $1.75B convertible bond offering at 0.25% coupon, conversion price $148.20. Total debt is $7.3B vs $2.1B cash. D/E ratio of 131%. While leverage is manageable (ND/EBITDA 1.3x, interest coverage 14.9x), the convertible was issued at $148.20 when the stock was trading near that level -- and now trades at $125.64, meaning the company essentially bought back shares at ~18% higher than current price.
- **Probabilidad:** Media -- the buyback at elevated prices is a sunk cost. Future risk is that debt maturity schedule ($750M in 2027, $1,350M in 2028) coincides with continued earnings pressure.
- **Impacto:** Medio -- value destruction from overpaying for buybacks is real but limited. The convertible at $148.20 is currently out-of-the-money, meaning no dilution unless the stock recovers significantly.

### 7. Antibiotic Resistance Regulations (ESG)

- **Descripcion:** FAIRR Initiative found Zoetis lacks comprehensive policy for tackling antimicrobial resistance. EU regulations (2019/6, 2019/4) restrict non-essential antimicrobial use. Zoetis still labels some products for growth promotion in Latin America.
- **Probabilidad:** Media -- regulatory tightening is a slow trend.
- **Impacto:** Medio -- livestock antibiotics are meaningful but Zoetis' vaccine portfolio is well-positioned for the shift. The reputational risk from being seen as "fueling irresponsible antimicrobial use" is arguably more damaging than revenue impact.

### 8. Livestock Cyclicality (ASF, Avian Flu)

- **Descripcion:** African Swine Fever remains active globally (Eastern Europe, SE Asia, Africa). HPAI continues to affect poultry and has spread to US dairy cattle. However, disease outbreaks are typically POSITIVE for Zoetis (more vaccine demand) rather than negative. The real livestock risk is cyclical demand downturn (beef/pork exports forecast to decline in 2026).
- **Probabilidad:** Media for cyclical downturn; Baja for catastrophic disease wiping out livestock demand.
- **Impacto:** Bajo-Medio -- livestock is ~35% of revenue but more diversified geographically. Brazil livestock was a key growth driver in 2025.

### 9. GLP-1 Drugs for Pets (Emerging)

- **Descripcion:** Okava Pharmaceuticals launched MEOW-1 clinical study for GLP-1 implant in cats (OKV-119). About 60% of US cats are overweight. Target cost: ~$100/month.
- **Probabilidad:** Baja for 2026-2028 impact. These are in early clinical trials.
- **Impacto:** Medio long-term -- if GLP-1 for pets becomes a major category, Zoetis could be a developer OR a victim depending on its pipeline. Not competitive with dermatology (different indication). Could actually be an opportunity if Zoetis develops its own version.

### 10. IDEXX Diagnostics Dominance

- **Descripcion:** IDEXX leads veterinary diagnostics with significantly higher market share and investment. Zoetis is a distant competitor despite launching VetScan OptiCell (AI-powered hematology). The diagnostics market is growing at ~9.5% CAGR but IDEXX has "distanced itself" from competitors.
- **Probabilidad:** Media -- IDEXX's lead is structural.
- **Impacto:** Bajo -- diagnostics is a growth driver but not Zoetis' core profit engine. The risk is that diagnostics fails to offset declining legacy products, not that it becomes a loss-maker.

---

## Riesgos NO Mencionados en Thesis

No thesis exists yet for ZTS. These are the risks that a fundamental analyst might minimize or overlook:

| Riesgo | Severidad | Likely Thesis Treatment | Comentario |
|--------|-----------|------------------------|------------|
| Librela franchise collapse (already -32% US Q4) | CRITICAL | May acknowledge but downplay as "temporary" | This is NOT temporary. Vet confidence takes years to rebuild. WSJ articles, FDA letters, consumer advocacy sites -- the damage is structural |
| EU antitrust novel theory (ranevetmab shelving) | HIGH | May dismiss as "unlikely to result in fine" | The fine risk is real but the LICENSING risk is worse -- forcing Zoetis to give a competitor its own biological product |
| Buyback at inflated prices ($3.2B in 2025 at ~$140-170) | MEDIUM | Likely praised as "shareholder-friendly" | This is value destruction. $3.2B in buybacks when stock subsequently fell 25%+ is poor capital allocation |
| Convertible bond at $148.20 while stock is $125 | MEDIUM | May ignore or call "manageable" | Converts are now underwater from shareholder perspective; company borrowed $1.75B to buy back stock above current price |
| Vet visit secular decline (-2-4% YoY) | HIGH | May treat as cyclical | Research suggests this is partly structural (affordability, vet shortage, telehealth alternatives). May persist beyond mid-2026 |
| Insider ownership 0.1% | LOW | Probably ignored | Extremely low insider ownership means management has minimal skin in the game on downside. Institutional ownership 98.2% |
| Growth deceleration masks maturation | HIGH | May project 6-7% forward growth | Management itself guided 3-5%. The thesis analyst may use historical 6% or higher |

---

## Kill Conditions Sugeridas

1. **Librela FDA restriction:** If FDA issues mandatory label change restricting Librela use to specific cases, or requires REMS (Risk Evaluation and Mitigation Strategy), or withdraws approval -- EXIT immediately. This would devastate the OA franchise and signal regulatory severity.

2. **EU antitrust finding + ranevetmab licensing order:** If the European Commission finds abuse of dominance AND orders Zoetis to license ranevetmab to Virbac, creating a direct biological competitor in Europe -- EXIT. This would open a second front of OA franchise erosion.

3. **US companion animal revenue decline >5% for 2 consecutive quarters:** This would indicate that the combination of Librela safety issues + vet visit decline is causing structural shrinkage in Zoetis' highest-margin business.

4. **Dermatology franchise revenue decline >10% YoY (post-generic entry):** If Apoquel generics capture share faster than the "rational pricing" assumption suggests, indicating the dermatology moat is weaker than assumed.

5. **Net Debt/EBITDA exceeds 2.5x:** If management continues aggressive buybacks despite earnings pressure and leverage climbs, this would signal capital allocation indiscipline at a time when the business needs investment in pipeline.

6. **Multiple analyst downgrades to Sell (currently 0 Sell ratings):** If the consensus shifts from "moderate buy" (6 buy, 6 hold, 0 sell) to include multiple sell ratings, this would indicate institutional consensus has shifted to structural bearish.

---

## Riesgo Agregado

- **Numero de riesgos HIGH+CRITICAL:** 5 (1 CRITICAL, 4 HIGH)
- **Riesgos correlacionados?** YES -- Risks #1, #2, #4, and #5 are HIGHLY correlated. They all relate to the same fundamental issue: Zoetis' key companion animal franchises (OA pain + dermatology) are simultaneously under pressure from safety concerns, regulatory scrutiny, competitive entry, and volume decline. If Librela continues to decline AND dermatology matures AND vet visits don't recover, the growth algorithm breaks down. This correlation is the most dangerous aspect of the risk profile -- these are not independent risks.
- **Second correlation cluster:** Risks #5 (growth deceleration) + #6 (debt-funded buybacks) are correlated. If growth decelerates below 3%, the leverage from buybacks becomes burdensome rather than accretive, and the stock bought at $140-170 becomes a permanent capital destruction.
- **Risk Score Final: HIGH**

---

## Quantified Downside Scenarios

| Scenario | Probability | Price Impact | Resulting Price |
|----------|-------------|-------------|-----------------|
| **Bull:** Librela stabilizes, vet visits recover, 5% growth | 25% | +30-40% | $165-175 |
| **Base:** Librela flat, vet visits slowly recover, 3-4% growth | 40% | +5-15% | $130-145 |
| **Bear:** Librela continues declining, generics hit Apoquel early, 2-3% growth | 25% | -15-25% | $95-107 |
| **Severe Bear:** Librela pulled/restricted + EU antitrust fine + recession | 10% | -35-50% | $65-82 |

**Expected value-weighted price:** ~$127-135 (roughly current levels), suggesting the stock is approximately fairly priced for the risk-adjusted outlook. This means limited margin of safety unless you believe the bull case has higher probability than assigned above.

---

## ðŸ”„ META-REFLECTION

### Dudas/Incertidumbres
- **Librela trajectory uncertainty:** I cannot determine with confidence whether the Q4 -32% US decline represents the trough or an acceleration. Management says "headwinds persist into 2026" but also claims the strategy will "return to growth." The truth depends on veterinarian confidence, which is qualitative and hard to measure.
- **EU antitrust timeline and outcome:** This is a novel legal theory with no precedent. I assign Media probability to a finding, but I genuinely do not know how this will resolve. The fine risk ($0-950M range) is extremely wide.
- **Generic pricing behavior in animal health:** I rely on the claim that animal health generics are "more rational" than human pharma, but this assumption could be wrong if new entrants (e.g., Indian generics manufacturers) enter the market with aggressive pricing.
- **yfinance rate limiting prevented initial tool run:** I was rate-limited initially and had to retry. The quality scorer data is now obtained but the delay meant I could not cross-validate financial data from multiple tool sources.

### Riesgos que Podrian Estar Subestimados
- **Veterinary visit secular decline:** I classified this as HIGH but it could be CRITICAL if the affordability trend is structural rather than cyclical. 64% of lower-income pet owners say they can't afford vet care -- this is a demand ceiling that may not respond to interest rate cuts.
- **Capital allocation indiscipline:** The $3.2B in buybacks at $140-170 while the stock is now $125 is a meaningful value destruction event that I classified as MEDIUM. If management continues this pattern (using debt to buy back stock during a downturn), it could compound into a larger problem.
- **Insider ownership 0.1%:** This is exceptionally low. Combined with 98.2% institutional ownership, it means management's incentive alignment is primarily through options/RSUs (which are repriced or awarded at new levels) rather than permanent capital at risk. I scored this LOW but the behavioral implications could be meaningful.

### Discrepancias Potenciales con Future Thesis
- A fundamental analyst may assign Tier A status (QS 73 is borderline B/A) based on the exceptional ROIC (30.3%) and margins. I would argue the QS of 73 is appropriate or even generous given:
  - Growth deceleration (3-5% vs 6% historical) should reduce Growth score
  - Moat under active siege (Librela safety, Apoquel generics, EU antitrust) should reduce Moat score
  - Capital allocation (buybacks at elevated prices, low insider ownership) is not optimal
- A thesis might project 6-7% growth resumption based on "innovation pipeline." I see 3-5% as the new normal unless there's a breakthrough product (which I cannot identify in the pipeline).
- The fair value in a thesis might anchor on historical P/E of 30-35x. Given decelerated growth, I believe 20-25x is more appropriate, implying FV of $140-175 (vs historical premium of $180+).

### Sugerencias para el Sistema
- **Add "product safety crisis" as a standard risk factor in risk-identifier template.** Librela/Solensia is a template case of how a blockbuster product can turn into a liability. Similar risk applies to any pharma/biotech position.
- **Add "capital allocation quality" assessment beyond the QS payout ratio metric.** Zoetis' QS gives 5/5 for shareholder return but doesn't penalize for buying back stock at inflated prices. A more sophisticated metric would compare buyback price vs intrinsic value.
- **Veterinary industry macro data** should be tracked as a sector-level indicator if we invest in animal health (ZTS, IDEXX, etc.). Vet visit trends are leading indicators.

### Preguntas para Orchestrator
1. Given the CRITICAL Librela risk and HIGH correlated risk cluster, does the overall risk profile warrant proceeding to full buy-pipeline, or should we wait for Librela stabilization evidence (2-3 quarters of flat-to-positive US revenue)?
2. The convertible bond at $148.20 conversion price -- should this be viewed as a signal that management believed the stock was undervalued at $148 (bullish) or as evidence of poor timing/capital allocation (bearish)?
3. With 0.1% insider ownership, does Zoetis meet our governance standards? Most of our Tier A/B holdings have higher insider alignment. Should this be weighted more heavily?
4. The EU antitrust case is unprecedented (first abuse-of-dominance for shelving a pipeline product). Should we engage a specialist legal view or is the publicly available expert opinion sufficient to assess probability?

---

## Sources

### Financial Results & Guidance
- [Zoetis Q4/FY2025 Results](https://investor.zoetis.com/news/news-details/2026/Zoetis-Reports-Fourth-Quarter-and-Full-Year-2025-Results/default.aspx)
- [Zoetis Q4 2025 Earnings Call Transcript - Motley Fool](https://www.fool.com/earnings/call-transcripts/2026/02/12/zoetis-zts-q4-2025-earnings-call-transcript/)
- [Zoetis Q4 Slides - Investing.com](https://www.investing.com/news/company-news/zoetis-q4-2025-slides-6-annual-growth-achieved-35-projected-for-2026-93CH-4503431)
- [Zoetis Earnings Dip - GuruFocus](https://www.gurufocus.com/news/8611346/zoetis-zts-shares-dip-despite-beating-q4-2025-expectations)
- [Zoetis Stock Plummets 24.8% YTD - Yahoo Finance](https://finance.yahoo.com/news/zoetis-stock-plummets-24-8-144700688.html)

### Librela/Solensia Safety
- [Zoetis Statement on Librela Safety](https://news.zoetis.com/press-releases/press-release-details/2024/Zoetis-Statement-on-the-Safety-of-Librela/default.aspx)
- [FDA Adverse Events Notification - dvm360](https://www.dvm360.com/view/fda-notifies-veterinarians-of-adverse-events-linked-to-osteoarthritis-treatment)
- [FDA Warning Letter re: YouTube Marketing - FDA.gov](https://www.fda.gov/media/185684/download)
- [Stop Zoetis Consumer Advocacy](https://stopzoetis.org/)
- [Zoetis Stock Crumbles - Yahoo Finance](https://finance.yahoo.com/news/animal-health-giant-zoetis-stock-173055027.html)

### EU Antitrust Investigation
- [EC Opens Investigation - Goodwin Law](https://www.goodwinlaw.com/en/insights/publications/2024/04/insights-otherindustries-european-commission-launches-antitrust-investigation)
- [EC Press Corner - Antitrust Zoetis](https://ec.europa.eu/commission/presscorner/detail/en/ip_24_1687)
- [Van Bael & Bellis Analysis](https://www.vbb.com/insights/european-commission-opens-abuse-of-dominance-investigation-against-zoetis)
- [Hogan Lovells - Pipeline Drug Investigation](https://www.hoganlovells.com/en/publications/commission-investigation-into-termination-of-pipeline-drug-what-next-for-rd-decision-making)

### Competition & Patents
- [0to1 Stock Market - Zoetis Industry Research](https://www.0to1stockmarket.com/p/research-zoetis-industry)
- [IDEXX, Mars, Zoetis Diagnostics - Science and Medicine Group](https://www.scienceandmedicinegroup.com/veterinary-diagnostic-leaders/)

### Veterinary Visit Decline
- [Zoetis Outlook Cut - Simply Wall St](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-zts/zoetis/news/zoetis-outlook-cut-highlights-slower-vet-visits-and-long-ter/amp)
- [Veterinary Visits Decline - dvm360](https://www.dvm360.com/view/veterinary-visits-decline-as-clients-face-rising-costs-data-reveals)
- [Zoetis Faces Earnings Test - Investing.com](https://ng.investing.com/news/earnings/zoetis-faces-earnings-test-as-vet-visit-decline-weighs-93CH-2337475)

### GLP-1 for Pets
- [GLP-1 Implant for Pets - Drugs.com](https://www.drugs.com/news/new-glp-1-implant-may-help-overweight-pets-study-underway-127841.html)
- [Pet Weight Loss Drugs - Pet Obesity Prevention](https://www.petobesityprevention.org/articlesandnews/3wd6dsda1bpq1t4k7dgwsz2md3nm7p)
- [GLP-1 Cat Trial - CBS News](https://www.cbsnews.com/news/pets-glp1-weight-loss-drugs-clinical-study-cats/)

### ESG / Antibiotics
- [FAIRR Report on Animal Health AMR](https://www.fairr.org/news-events/press-releases/animal-health-sector-fuelling-irresponsible-antimicrobial-use-in-meat-supply-chains)
- [Zoetis Position on Antibiotics](https://www.zoetis.com/our-company/position-on-responsible-use-of-antibiotics-in-animals)

### Analyst Ratings
- [Analyst Price Target Revisions - Benzinga](https://www.benzinga.com/analyst-stock-ratings/price-target/26/02/50566792/top-wall-street-forecasters-revamp-zoetis-expectations-ahead-of-q4-earnings)
- [Analysts Question Growth Path - Benzinga](https://www.benzinga.com/markets/earnings/26/02/50588760/analysts-question-zoetis-pathway-to-growth-as-key-segments-slide)
- [ZTS Forecast - Public.com](https://public.com/stocks/zts/forecast-price-target)

### Insider Activity
- [ZTS Insider Trades - MarketBeat](https://www.marketbeat.com/stocks/NYSE/ZTS/insider-trades/)
- [ZTS Insider Trading - Fintel](https://fintel.io/sn/us/zts)

### Convertible Bond
- [Zoetis $1.75B Convertible Notes - Investor Relations](https://investor.zoetis.com/news/news-details/2025/Zoetis-Announces-Pricing-of-1-75-Billion-Convertible-Senior-Notes-Offering/default.aspx)
- [Convertible Bond Analysis - AInvest](https://www.ainvest.com/news/zoetis-1-75-billion-convertible-bond-offering-strategic-share-buybacks-stock-price-manipulation-2512/)

### Legal
- [Employee Class Action - ZoetisLawsuit.com](https://www.zoetislawsuit.com/)
- [Securities Investigation - GlobeNewsWire](https://www.globenewswire.com/news-release/2024/04/19/2866336/23044/en/SHAREHOLDER-ALERT-Zoetis-Investigated-by-Block-Leviton-For-Potential-Securities-Law-Violations-Investors-Who-Have-Lost-Money-Are-Encouraged-to-Contact-the-Firm.html)
